Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive...

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan...

Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer ( Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA )

Melanoma outcomes improved by dual immunotherapy before surgery rather than...

Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands

Melanoma outcomes improved by dual immunotherapy before surgery rather than after ( Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands )

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Prof Don Dizon - Lifespan Cancer Institute, Providence, USA

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas ( Prof Don Dizon - Lifespan Cancer Institute, Providence, USA )

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for...

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )

CAR-T, bispecifics or ADCs in late-stage RRMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy

CAR-T, bispecifics or ADCs in late-stage RRMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Treatment of multiple myeloma in Turkey

Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey

Treatment of multiple myeloma in Turkey ( Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey )

Linvoseltamab induces deep and durable responses in patients with relapsed or...

Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA

$Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma ( Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA )$

More from ecancer